Moxifloxacin Reiwa Healthcare

Moxifloxacin, the active ingredient in Moxifloxacin Reiwa Healthcare, is a fluoroquinolone antibiotic presented as an injectable solution for intravenous use. It is indicated for the treatment of serious bacterial infections such as community‑acquired pneumonia, acute sinusitis, exacerbations of chronic bronchitis, skin and soft‑tissue infections, and intra‑abdominal infections in adult patients.

GNH USA supplies Moxifloxacin Reiwa Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable medicines.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections affecting the respiratory, skin, and intra‑abdominal systems.

- Community‑acquired bacterial pneumonia: achieves bacterial eradication and clinical cure in adult patients. - Acute bacterial sinusitis: reduces symptoms and eliminates the causative pathogens. - Acute bacterial exacerbation of chronic bronchitis: improves lung function and shortens disease duration. - Skin and skin structure infections: resolves infection and promotes healing of affected tissues. - Intra‑abdominal infections: provides effective antimicrobial coverage for mixed‑organism infections.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Rash

Serious or Rare Side Effects: - Tendon rupture or inflammation - QT interval prolongation leading to arrhythmia - Severe allergic reactions such as anaphylaxis - Clostridioides difficile‑associated colitis

When prescribing Moxifloxacin, clinicians should consider several safety precautions to minimize risks.

- Renal impairment: monitor renal function and adjust therapy as needed. - History of tendon disorders: avoid use due to increased risk of tendon rupture. - Prolonged QT interval: obtain baseline ECG and avoid concomitant QT‑prolonging drugs. - Pregnancy Category B: prescribe only when the potential benefit justifies the potential risk. - Concurrent antacids or multivitamins containing aluminum or magnesium: separate administration by at least 2 hours to ensure absorption. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Co‑administration with other fluoroquinolones: may increase toxicity without added benefit. - Drugs that prolong the QT interval (e.g., macrolides, antiarrhythmics): heightened risk of cardiac arrhythmias. - Concurrent use of non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of central nervous system stimulation and seizures.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: reduce oral absorption; separate dosing. - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Corticosteroids: combined use raises the chance of tendon injury.